UP!

JUNO $86.96

JUNO target price
86.96
0
0
Juno Therapeutics Inc
Type
Public
Traded as NASDAQ: JUNO
Industry Biotechnology
Founded 2013
Headquarters Seattle, WA
Key people

Hans Bishop (CEO & President)
Steve Harr, M.D. (CFO)
Hyam Levitsky, M.D. (CSO)

Mark Gilbert, M.D. (CMO)
Website junotherapeutics.com

Hans Bishop (CEO & President)
Steve Harr, M.D. (CFO)
Hyam Levitsky, M.D. (CSO)

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.

In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22.

In April 2015 the company entered into a collaboration with MedImmune (a subsidiary of Astra Zeneca) investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Juno's CD19 directed chimeric antigen receptor T cell candidates. In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. In June, the company announced it would acquire X-Body for more than $44 million. In June, the company announced a 10-year partnership with Celgene valued at $1 billion. As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno’s therapies around the world. This partnership surpasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014.

In January 2016 Juno announced it had acquired AbVitro, allowing it to use next-generation single cell sequencing platforms to complement its ability to create T cells engineered to target a broad array of cancer targets. Later in July of the same year, the company announced it would acquire RedoxTherapies for $10 million. This acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers. In August the company announced it would license rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for a novel, fully human binding domain targeting B-cell maturation antigen.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-07-10 Reiterated Rating Maxim Group Buy $80.00
2016-07-10 Reiterated Rating Cowen and Company Buy $55.00
2016-07-09 Reiterated Rating FBR & Co Buy
2016-07-08 Reiterated Rating Leerink Swann Outperform $60.00
2016-07-08 Downgrade JPMorgan Chase & Co. Overweight to Neutral $63.00 to $39.00
2016-07-08 Lower Price Target FBR & Co Outperform $73.00 to $61.00
2016-07-06 Initiated Coverage Barclays PLC Equal Weight $48.00
2016-06-06 Reiterated Rating FBR & Co. Buy
2016-06-06 Reiterated Rating FBR & Co Buy
2016-06-02 Initiated Coverage Raymond James Outperform $52.00
2016-06-02 Initiated Coverage Raymond James Financial Inc. Outperform $52.00
2016-05-10 Reiterated Rating FBR & Co. Buy
2016-05-05 Initiated Coverage Cowen and Company Outperform $55.00
2016-04-20 Reiterated Rating SunTrust Buy $50.00
2016-04-20 Reiterated Rating SunTrust Banks Inc. Buy $50.00
2016-04-11 Reiterated Rating Maxim Group Buy $78.00 to $80.00
2016-04-09 Reiterated Rating FBR & Co. Buy $73.00
2016-04-08 Boost Price Target Morgan Stanley $48.00 to $50.00
2016-03-20 Reiterated Rating SunTrust Buy $50.00
2016-03-18 Reiterated Rating Leerink Swann Outperform $67.00
2016-03-02 Lower Price Target Leerink Swann Outperform $65.00 to $60.00
2016-03-02 Reiterated Rating FBR & Co. Outperform $73.00
2016-02-27 Initiated Coverage Deutsche Bank Buy
2016-02-27 Initiated Coverage Deutsche Bank AG Buy
2016-02-25 Initiated Coverage Citigroup Inc. Buy $45.00
2016-02-22 Lower Price Target Goldman Sachs $50.00 to $41.00
2016-02-22 Lower Price Target Goldman Sachs Group Inc. $50.00 to $41.00
2016-02-17 Reiterated Rating Maxim Group Buy $78.00
2016-02-17 Upgrade Guggenheim Neutral to Buy
2016-01-28 Initiated Coverage SunTrust Buy $50.00
2016-01-13 Reiterated Rating JPMorgan Chase & Co. Overweight $69.00
2016-01-11 Reiterated Rating FBR & Co. Buy $73.00
2015-12-15 Upgrade Standpoint Research Hold to Buy
2015-12-08 Reiterated Rating FBR & Co. Outperform $73.00
2015-11-30 Reiterated Rating Leerink Swann Outperform
2015-11-18 Initiated Coverage Goldman Sachs Neutral $50.00
2015-11-11 Boost Price Target Leerink Swann $56.00 to $65.00
2015-11-11 Lower Price Target JPMorgan Chase & Co. Overweight $70.00 to $69.00
2015-10-29 Downgrade Standpoint Research Buy to Hold
2015-10-06 Reiterated Rating FBR & Co. Outperform $73.00
2015-09-16 Reiterated Rating JPMorgan Chase & Co. Buy $70.00
2015-08-24 Initiated Coverage Standpoint Research Buy $47.00
2015-08-18 Initiated Coverage FBR & Co. Outperform $73.00
2015-08-17 Lower Price Target Morgan Stanley $54.00 to $53.00
2015-08-13 Reiterated Rating JPMorgan Chase & Co. Buy $83.00 to $70.00
2015-08-04 Reiterated Rating Maxim Group Buy $78.00
2015-07-22 Initiated Coverage Northland Securities Outperform $64.00
2015-07-20 Lower Price Target Goldman Sachs Neutral $52.00 to $51.00
2015-06-30 Lower Price Target Morgan Stanley Equal Weight $59.00 to $54.00
2015-06-30 Reiterated Rating Maxim Group Buy
2015-06-30 Boost Price Target JPMorgan Chase & Co. Overweight $66.00 to $83.00
2015-06-18 Initiated Coverage Maxim Group Buy $78.00
2015-05-28 Reiterated Rating JPMorgan Chase & Co. Overweight $66.00
2015-05-14 Reiterated Rating JPMorgan Chase & Co. Overweight $66.00
2015-05-13 Reiterated Rating Leerink Swann Outperform $74.00
2015-04-06 Reiterated Rating JPMorgan Chase & Co. Buy
2015-03-19 Reiterated Rating JPMorgan Chase & Co. Overweight $66.00
2015-01-13 Initiated Coverage Leerink Swann Outperform $74.00
2015-01-13 Initiated Coverage JPMorgan Chase & Co. Overweight $66.00
2015-01-13 Initiated Coverage Goldman Sachs Neutral $52.00
2016-07-10 Reiterated Rating Maxim Group Buy $80.00
2016-07-10 Reiterated Rating Cowen and Company Buy $55.00
2016-07-09 Reiterated Rating FBR & Co Buy
2016-07-08 Reiterated Rating Leerink Swann Outperform $60.00
2016-07-08 Downgrade JPMorgan Chase & Co. Overweight to Neutral $63.00 to $39.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks